MaxCyte (MXCT) Competitors

MaxCyte logo
GBX 1.17 -0.01 (-0.85%)
As of 11/17/2026

MXCT vs. GENI, IDHC, DMTR, LLAI, and LLA

Should you buy MaxCyte stock or one of its competitors? MaxCyte's main competitors and comparable companies include GENinCode (GENI), Integrated Diagnostics (IDHC), Deepmatter Group (DMTR), LungLife AI (LLAI), and LLA.L,0P0001T9GN,0 (LLA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "life sciences tools & services" industry.

How does MaxCyte compare to GENinCode?

MaxCyte (LON:MXCT) and GENinCode (LON:GENI) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

MaxCyte has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, GENinCode has a beta of 0.59, meaning that its stock price is 41% less volatile than the broader market.

MaxCyte has a net margin of -106.29% compared to GENinCode's net margin of -202.42%. MaxCyte's return on equity of -18.73% beat GENinCode's return on equity.

Company Net Margins Return on Equity Return on Assets
MaxCyte-106.29% -18.73% -11.07%
GENinCode -202.42%-481.34%-63.99%

24.0% of MaxCyte shares are held by institutional investors. Comparatively, 2.8% of GENinCode shares are held by institutional investors. 1.9% of MaxCyte shares are held by insiders. Comparatively, 8.4% of GENinCode shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

GENinCode has lower revenue, but higher earnings than MaxCyte. GENinCode is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MaxCyte£32.29M0.04-£45.08M-£40.00N/A
GENinCode£2.60M1.67-£6.10M-£1.27N/A

In the previous week, MaxCyte had 1 more articles in the media than GENinCode. MarketBeat recorded 1 mentions for MaxCyte and 0 mentions for GENinCode. MaxCyte's average media sentiment score of 1.19 beat GENinCode's score of 0.00 indicating that MaxCyte is being referred to more favorably in the media.

Company Overall Sentiment
MaxCyte Positive
GENinCode Neutral

Summary

MaxCyte beats GENinCode on 9 of the 13 factors compared between the two stocks.

How does MaxCyte compare to Integrated Diagnostics?

MaxCyte (LON:MXCT) and Integrated Diagnostics (LON:IDHC) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

In the previous week, MaxCyte had 1 more articles in the media than Integrated Diagnostics. MarketBeat recorded 1 mentions for MaxCyte and 0 mentions for Integrated Diagnostics. MaxCyte's average media sentiment score of 1.19 beat Integrated Diagnostics' score of 0.00 indicating that MaxCyte is being referred to more favorably in the media.

Company Overall Sentiment
MaxCyte Positive
Integrated Diagnostics Neutral

MaxCyte has a beta of 1.13, indicating that its stock price is 13% more volatile than the broader market. Comparatively, Integrated Diagnostics has a beta of 0.442, indicating that its stock price is 56% less volatile than the broader market.

24.0% of MaxCyte shares are owned by institutional investors. Comparatively, 7.7% of Integrated Diagnostics shares are owned by institutional investors. 1.9% of MaxCyte shares are owned by insiders. Comparatively, 81.1% of Integrated Diagnostics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Integrated Diagnostics has higher revenue and earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Integrated Diagnostics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MaxCyte£32.29M0.04-£45.08M-£40.00N/A
Integrated Diagnostics£9.17B0.00£4.01T£263.000.00

Integrated Diagnostics has a net margin of 16.49% compared to MaxCyte's net margin of -106.29%. Integrated Diagnostics' return on equity of 39.61% beat MaxCyte's return on equity.

Company Net Margins Return on Equity Return on Assets
MaxCyte-106.29% -18.73% -11.07%
Integrated Diagnostics 16.49%39.61%9.69%

Summary

Integrated Diagnostics beats MaxCyte on 8 of the 13 factors compared between the two stocks.

How does MaxCyte compare to Deepmatter Group?

Deepmatter Group (LON:DMTR) and MaxCyte (LON:MXCT) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

24.0% of MaxCyte shares are held by institutional investors. 1.9% of MaxCyte shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Deepmatter Group has a net margin of 0.00% compared to MaxCyte's net margin of -106.29%. Deepmatter Group's return on equity of 0.00% beat MaxCyte's return on equity.

Company Net Margins Return on Equity Return on Assets
Deepmatter GroupN/A N/A N/A
MaxCyte -106.29%-18.73%-11.07%

Deepmatter Group has higher earnings, but lower revenue than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than Deepmatter Group, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Deepmatter Group£1.04M0.00N/A-£0.30N/A
MaxCyte£32.29M0.04-£45.08M-£40.00N/A

In the previous week, MaxCyte had 1 more articles in the media than Deepmatter Group. MarketBeat recorded 1 mentions for MaxCyte and 0 mentions for Deepmatter Group. MaxCyte's average media sentiment score of 1.19 beat Deepmatter Group's score of 0.00 indicating that MaxCyte is being referred to more favorably in the news media.

Company Overall Sentiment
Deepmatter Group Neutral
MaxCyte Positive

Summary

MaxCyte beats Deepmatter Group on 6 of the 10 factors compared between the two stocks.

How does MaxCyte compare to LungLife AI?

MaxCyte (LON:MXCT) and LungLife AI (LON:LLAI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings, media sentiment and valuation.

MaxCyte has a beta of 1.13, meaning that its stock price is 13% more volatile than the broader market. Comparatively, LungLife AI has a beta of -0.3, meaning that its stock price is 130% less volatile than the broader market.

24.0% of MaxCyte shares are owned by institutional investors. Comparatively, 42.5% of LungLife AI shares are owned by institutional investors. 1.9% of MaxCyte shares are owned by company insiders. Comparatively, 48.4% of LungLife AI shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

MaxCyte has a net margin of -106.29% compared to LungLife AI's net margin of -11,767.39%. MaxCyte's return on equity of -18.73% beat LungLife AI's return on equity.

Company Net Margins Return on Equity Return on Assets
MaxCyte-106.29% -18.73% -11.07%
LungLife AI -11,767.39%-51.42%-27.28%

In the previous week, MaxCyte had 1 more articles in the media than LungLife AI. MarketBeat recorded 1 mentions for MaxCyte and 0 mentions for LungLife AI. MaxCyte's average media sentiment score of 1.19 beat LungLife AI's score of 0.00 indicating that MaxCyte is being referred to more favorably in the media.

Company Overall Sentiment
MaxCyte Positive
LungLife AI Neutral

LungLife AI has lower revenue, but higher earnings than MaxCyte. LungLife AI is trading at a lower price-to-earnings ratio than MaxCyte, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MaxCyte£32.29M0.04-£45.08M-£40.00N/A
LungLife AI£33.87K34.24-£5.22M-£12.58N/A

Summary

MaxCyte beats LungLife AI on 8 of the 13 factors compared between the two stocks.

How does MaxCyte compare to LLA.L,0P0001T9GN,0?

MaxCyte (LON:MXCT) and LLA.L,0P0001T9GN,0 (LON:LLA) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, media sentiment, institutional ownership, earnings, profitability and dividends.

24.0% of MaxCyte shares are owned by institutional investors. Comparatively, 5.4% of LLA.L,0P0001T9GN,0 shares are owned by institutional investors. 1.9% of MaxCyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, MaxCyte had 1 more articles in the media than LLA.L,0P0001T9GN,0. MarketBeat recorded 1 mentions for MaxCyte and 0 mentions for LLA.L,0P0001T9GN,0. MaxCyte's average media sentiment score of 1.19 beat LLA.L,0P0001T9GN,0's score of 0.00 indicating that MaxCyte is being referred to more favorably in the media.

Company Overall Sentiment
MaxCyte Positive
LLA.L,0P0001T9GN,0 Neutral

LLA.L,0P0001T9GN,0 has lower revenue, but higher earnings than MaxCyte. MaxCyte is trading at a lower price-to-earnings ratio than LLA.L,0P0001T9GN,0, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MaxCyte£32.29M0.04-£45.08M-£40.00N/A
LLA.L,0P0001T9GN,0N/AN/A-£4.47M-£0.12N/A

LLA.L,0P0001T9GN,0 has a net margin of 0.00% compared to MaxCyte's net margin of -106.29%. MaxCyte's return on equity of -18.73% beat LLA.L,0P0001T9GN,0's return on equity.

Company Net Margins Return on Equity Return on Assets
MaxCyte-106.29% -18.73% -11.07%
LLA.L,0P0001T9GN,0 N/A -48.59%-27.28%

MaxCyte has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market. Comparatively, LLA.L,0P0001T9GN,0 has a beta of -0.3, meaning that its share price is 130% less volatile than the broader market.

Summary

MaxCyte beats LLA.L,0P0001T9GN,0 on 9 of the 12 factors compared between the two stocks.

Get MaxCyte News Delivered to You Automatically

Sign up to receive the latest news and ratings for MXCT and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MXCT vs. The Competition

MetricMaxCyteLife Sciences Tools & Services IndustryHealthcare SectorLON Exchange
Market Cap£1.24M£10.76B£7.72B£2.74B
Dividend YieldN/A1.46%2.47%5.11%
P/E Ratio-0.0351.2132.9523.17
Price / Sales0.047.448.215.06
Price / Cash1.9726.3620.8520.23
Price / Book0.014.414.432.46
Net Income-£45.08M£57.47B£3.51B£5.88B
7 Day Performance3.54%-2.11%-4.73%-1.74%
1 Month Performance-10.00%-1.51%-5.69%-3.52%
1 Year Performance-22.52%19.66%-1.18%6.90%

MaxCyte Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
MXCT
MaxCyte
N/AGBX 1.17
-0.8%
N/A-21.9%£1.24M£32.29MN/A80
GENI
GENinCode
N/AGBX 0.56
-6.7%
N/A-75.4%£4.22M£2.60MN/A2,300
IDHC
Integrated Diagnostics
N/AGBX 0.48
+1.1%
N/A-31.6%£2.77M£9.17B0.006,692
DMTR
Deepmatter Group
N/AN/AN/AN/A£1.33M£1.04MN/AN/A
LLAI
LungLife AI
N/AGBX 3.50
-17.6%
N/A+0.0%£1.16M£33.87KN/A15

Related Companies and Tools


This page (LON:MXCT) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners